Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.

Authors
  • Salmasinia, Donya
  • Chang, Myron
  • Wingard, John R
  • Hou, Wei
  • Moreb, Jan S
Type
Published Article
Journal
Clinical Medicine Insights. Oncology
Publication Date
Jan 01, 2010
Volume
4
Pages
117–125
Identifiers
DOI: 10.4137/CMO.S6161
PMID: 21151584
Source
Medline
Keywords
License
Unknown

Abstract

Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 4 × 10(6) units of IFN-α and 125 μg/m(2) of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seven others were taken off study due to flu-like symptoms and/or increase in liver enzymes. With a median follow-up of 45.5 months, the median overall survival was not reached while the median progression-free survival was 28 months. Eleven patients (42%) have remained in very good partial remission or complete remission since ASCT. In conclusion, our results demonstrate that maintenance with GM-CSF and IFN-α is safe and effective.

Report this publication

Statistics

Seen <100 times